China F&B Update: Health Food Regulations Tighten for Imported Products — Key Takeaways

China’s State Administration for Market Regulation (SAMR) has significantly tightened registration and labeling requirements for imported health foods (保健食品, health food, bǎojiàn shípǐn), with a new circular issued in Q4 2024 affecting **over 1,200** product categories. This update compels foreign manufacturers and importers to re-evaluate compliance strategies as approval timelines extend from the previous 12 months to a minimum of 18 months under revised protocols.

The 2024 SAMR circular introduces stricter efficacy claims standards, mandatory barcode traceability, and enhanced testing for imported products. Meanwhile, China’s health food market, valued at approximately 295 billion RMB in 2023, continues to grow at 11% year-on-year, making regulatory navigation critical. Below, we break down the key regulatory changes, provide a comparative data table, and outline three common pitfalls with their associated costs.

What the New Regulations Change

The SAMR circular, effective January 2025, targets three principal areas for imported health foods: registration documentation, safety testing protocols, and marketing label requirements. Under the new rules, foreign manufacturers must now submit 12 separate batches of stability testing data—up from 6 under the previous framework. Additionally, efficacy claims must be supported by China-specific clinical trial evidence for categories such as probiotics (益生菌, probiotics, yìshēng jūn) and herbal supplements (中草药补充剂, Chinese herbal supplements, zhōngcǎoyào bǔchōngjì).

For imported products, the revised rules also require a five-year market history in the country of origin, proving safe consumption prior to China market entry. Previously, a three-year history sufficed. This change alone has disqualified an estimated 230 overseas product registrations pending approval as of October 2024.

The labeling section is the most impactful: all ingredient disclosures must now include Chinese-language weight percentages for 100% of active ingredients—a move that caught many suppliers off guard. Failure to comply results in immediate rejection during the initial review phase, costing an average of 14,000 RMB per resubmission.

Comparative Data: Pre- and Post-Regulation Timeline

To visualize operational impact, the table below compares key metrics before and after the SAMR circular.

Foreign companies must also adjust to stricter oversight of online platform sales. The SAMR now mandates that imported health foods sold via cross-border e-commerce (跨境电商, cross-border e-commerce, kuàjìng diànshāng) carry a unique Chinese tracing code printed on each unit—failure to print and register these codes has already led to delisting of over 1,500 SKUs from Tmall Global and JD Worldwide in Q3 2024 alone.

Key Implications for Foreign Importers

The tightened regulations place an extra burden on foreign companies operating as a 外商独资企业 (WFOE, wàishāng dúzī qǐyè) in China or using a local importer-of-record structure. Two areas demand immediate attention: clinical trial acceptance and ingredient lists. The new rules now accept only China-based clinical trial data for efficacy claims—previously, foreign trials conducted under GCP standards were accepted. This forces foreign firms to budget for local clinical studies, which can cost between 300,000 RMB to 800,000 RMB per product claim.

Furthermore, ingredient lists must be disclosed at the individual compound level, even for proprietary blends. This affects about 40% of imported herbal supplements, which previously used generic descriptors like “proprietary blend” or “natural botanical extract.” The SAMR now requires each botanical to be listed with its Chinese pharmacopoeia identity number (CPNN).

Three Critical Pitfalls for Imported Health Food Companies

Strategic Response: What Executives Should Do in Q1 2025

To maintain market access and avoid disruption, foreign executives should take three immediate actions with their China compliance team:

1. Audit Your Current Registration Status

If you have pending applications filed before October 2024, check whether your stability testing batch count matches the new 12-batch requirement. Also verify that all supporting clinical trials meet the China GCP standard. Engage a qualified SAMR agent to perform a gap analysis—a common cost is 8,000–12,000 RMB per product.

2. Recalibrate Your Labeling and Packaging Strategy

All existing inventory destined for China must be reviewed for compliance with percentage-disclosure rules and tracing code inclusion. Work with a packaging engineering partner in Shanghai to modify artwork. Plan for a 6- to 8-week lead time for label revisions and pre-approval submissions.

3. Re-evaluate Your Market Entry Structure

If you currently use a third-party importer-of-record, consider transitioning to a wholly foreign-owned enterprise (WFOE) that holds its own health food registration. This gives you direct control over SAMR submissions and reduces dependency on potentially non-compliant local partners. A WFOE setup in Shanghai takes approximately 8–10 weeks and costs around 55,000 RMB in registration fees.

NEXT STEPS

Based on the analysis above, we recommend three concrete actions for executives managing China health food imports:

• Step 1: Read our comprehensive guide on China Health Food Registration 2025: Full Compliance Checklist to align your product portfolio with the new SAMR requirements.
• Step 2: Download the template for SAMR Label Compliance Checker to audit your current packaging against the percentage-disclosure and tracing code mandates.
• Step 3: Schedule a 30-minute consultation with our regulatory team via China F&B Market Entry Advisory to assess your registration gap and cost timeline.

— China Gateway 360 —
Remote China market entry support, built around execution.